bluebird bio Inc (BLUE)

71.68
NASDAQ : Health Care
Prev Close 73.30
Day Low/High 70.93 / 74.26
52 Wk Low/High 35.37 / 113.26
Avg Volume 1.08M
Exchange NASDAQ
Shares Outstanding 37.17M
Market Cap 2.72B
EPS -4.80
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

LentiGlobin™ Investigational Gene Therapy For Transfusion-Dependent Beta-Thalassemia Accepted Into European Medicines Agency's PRIME Program

LentiGlobin™ Investigational Gene Therapy For Transfusion-Dependent Beta-Thalassemia Accepted Into European Medicines Agency's PRIME Program

bluebird bio, Inc. ( Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today announced that...

Bluebird Bio (BLUE) Stock Jumping, Goldman Adds to Conviction Buy List

Bluebird Bio (BLUE) Stock Jumping, Goldman Adds to Conviction Buy List

Bluebird Bio (BLUE) stock was raised to 'conviction buy' at Goldman on Thursday.

Here's a Reason Why Bluebird Bio (BLUE) Stock Is Jumping Today

Here's a Reason Why Bluebird Bio (BLUE) Stock Is Jumping Today

Bluebird Bio (BLUE) could be a takeover target for Takeda Pharmaceutical (TKPYY), Citi said on Wednesday.

Bluebird Bio Announces Webcast Of Gene Therapy Day

Bluebird Bio Announces Webcast Of Gene Therapy Day

bluebird bio, Inc. ( Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today announced that it...

Bluebird Improves Its Gene Therapy, Removing an Investor Concern

Bluebird Improves Its Gene Therapy, Removing an Investor Concern

Bluebird Bio removed a significant concern investors had about its gene therapy manufacturing process, sending shares higher Thursday.

Bluebird Bio Opens Phase 3 Study Of LentiGlobin™ Drug Product In Patients With Transfusion-Dependent Beta-Thalassemia

Bluebird Bio Opens Phase 3 Study Of LentiGlobin™ Drug Product In Patients With Transfusion-Dependent Beta-Thalassemia

bluebird bio, Inc. (Nasdaq:BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today announced the...

Oncorus®, Inc. Appoints Biotech Industry Veteran Cyrus D. Mozayeni, M.D., As President And Chief Business Officer

Oncorus®, Inc. Appoints Biotech Industry Veteran Cyrus D. Mozayeni, M.D., As President And Chief Business Officer

- Former bluebird bio Global Head of Business Development Joins Newly Launched Immuno-Oncology Company -

Bluebird Bio To Present At Four Upcoming Conferences

Bluebird Bio To Present At Four Upcoming Conferences

bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today announced that...

Trade-Ideas: Bluebird Bio (BLUE) Is Today's

Trade-Ideas: Bluebird Bio (BLUE) Is Today's "Dead Cat Bounce" Stock

Trade-Ideas LLC identified bluebird bio (BLUE) as a "dead cat bounce" (down big yesterday but up big today) candidate

Bluebird Bio (BLUE) In A Perilous Reversal

Bluebird Bio (BLUE) In A Perilous Reversal

Trade-Ideas LLC identified bluebird bio (BLUE) as a "perilous reversal" (up big yesterday but down big today) candidate

Bluebird Bio To Present At Wedbush PacGrow Healthcare Conference

Bluebird Bio To Present At Wedbush PacGrow Healthcare Conference

bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today announced that...

Bluebird Bio Reports Second Quarter 2016 Financial Results And Recent Operational Progress

Bluebird Bio Reports Second Quarter 2016 Financial Results And Recent Operational Progress

bluebird bio, Inc. (Nasdaq: BLUE) a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today reported...

Bluebird Bio (BLUE) Weak On High Volume

Bluebird Bio (BLUE) Weak On High Volume

Trade-Ideas LLC identified bluebird bio (BLUE) as a weak on high relative volume candidate

4 Stocks to Play In Today's Market

4 Stocks to Play In Today's Market

Always trade the environment that you find yourself in.

Bluebird Bio (BLUE) Marked As A Barbarian At The Gate

Bluebird Bio (BLUE) Marked As A Barbarian At The Gate

Trade-Ideas LLC identified bluebird bio (BLUE) as a "barbarian at the gate" (strong stocks crossing above resistance with today's range greater than 200%) candidate

Insider Trading Alert - AA, BLUE And VLGEA Traded By Insiders

Insider Trading Alert - AA, BLUE And VLGEA Traded By Insiders

Stocks with insider trader activity include AA, BLUE and VLGEA

Celgene, Jounce Therapeutics in Early Cancer Immunotherapy Development Pact

Celgene, Jounce Therapeutics in Early Cancer Immunotherapy Development Pact

Celgene continues to sprinkle cash around the biotech sector, tying up with smaller companies for first-dibs access to potentially valuable drugs and technologies.

Bluebird Bio Presents MegaTAL Genome Editing Data At American Society Of Hematology (ASH) Workshop On Genome Editing

Bluebird Bio Presents MegaTAL Genome Editing Data At American Society Of Hematology (ASH) Workshop On Genome Editing

bluebird bio, Inc. (Nasdaq:BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today announced the...

Juno Patient Deaths Crash Cancer-Killing CAR-T Party

Juno Patient Deaths Crash Cancer-Killing CAR-T Party

The lead CAR-T program of Juno Therapeutics has been placed on a clinical hold by U.S. regulators following the deaths of two patients in a pivotal clinical trial.

Biotech Stock Mailbag: Mid-Year Assessment, Where We Go From Here

Biotech Stock Mailbag: Mid-Year Assessment, Where We Go From Here

TheStreet's Adam Feuerstein answers reader questions about biotech stocks.

A Biotech Stock Turnaround Requires an Alzheimer's Drug Miracle

A Biotech Stock Turnaround Requires an Alzheimer's Drug Miracle

What if the only sentiment-turning catalyst left for biotech stocks this year is the outcome of Eli Lilly's Alzheimer's phase III study expected around Christmas?

These 5 Stocks Could Be Toxic to Your Portfolio

These 5 Stocks Could Be Toxic to Your Portfolio

Is it time to unload these stocks from your portfolio?

Global Blood Shows Extended, Safe Treatment Effect for Sickle Cell Disease Drug

Global Blood Shows Extended, Safe Treatment Effect for Sickle Cell Disease Drug

New study results on GBT440 presented Friday should settle two big concerns investors have had with the Global Blood Therapeutics sickle cell disease drug.

Bluebird Bio (BLUE) Is Today's Dead Cat Bounce Stock

Bluebird Bio (BLUE) Is Today's Dead Cat Bounce Stock

Trade-Ideas LLC identified bluebird bio (BLUE) as a "dead cat bounce" (down big yesterday but up big today) candidate

Stock To Watch: Bluebird Bio (BLUE) In Perilous Reversal

Stock To Watch: Bluebird Bio (BLUE) In Perilous Reversal

Trade-Ideas LLC identified bluebird bio (BLUE) as a "perilous reversal" (up big yesterday but down big today) candidate

Bluebird Bio To Present At Goldman Sachs 37th Annual Healthcare Conference

Bluebird Bio To Present At Goldman Sachs 37th Annual Healthcare Conference

bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today announced that...

Bluebird Bio (BLUE) Showing Signs Of A Dead Cat Bounce Today

Bluebird Bio (BLUE) Showing Signs Of A Dead Cat Bounce Today

Trade-Ideas LLC identified bluebird bio (BLUE) as a "dead cat bounce" (down big yesterday but up big today) candidate

Mast Sickle Cell Drug Seeks to Defy Long Odds Like Leicester City

Mast Sickle Cell Drug Seeks to Defy Long Odds Like Leicester City

Very few people expect Mast's compound to become the first, new drug for sickle cell disease in almost 20 years. That's why Mast carries a miniscule $60 million market value.